Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rubinstein-Taybi Syndrome × mocetinostat × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Stomach Neoplasms 1 Rubinstein-Taybi Syndrome 1 Prostatic Neoplasms 1 Lung Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02236195 2017-09-01

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Mirati Therapeutics Inc.

Phase 2 Completed

Carcinoma, Transitional Cell, Rubinstein-Taybi Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡